Daptomycin Structure and Mechanism of Action Revealed  by Micklefield, Jason
Chemistry & Biology, Vol. 11, 887–895, July, 2004, 2004 Elsevier Ltd. All rights reserved. DOI 10.1016/j .chembiol .2004.07.001
Previews
neered biosynthesis of new products. For example, Mar-Daptomycin Structure
ahiel and coworkers have surgically replaced domainsand Mechanism of Action Revealed within NRPS modules or deleted whole modules by ma-
nipulation of the NRPS encoding genes responsible for
the biosynthesis of the cyclic lipopetide surfactin in Ba-
cillus subtilis. The resulting mutant strains produce new
Daptomycin kills otherwise antibiotic-resistant gram- surfactin derivatives of different amino acid sequence
positive pathogens and is the first lipopeptide antibi- and ring size [10, 11]. The key specificity-conferring
otic to reach the clinic. Elucidation of its 3D structure domain within an NRPS module is the adenylation (A)
and mechanism of action, reported in this issue of domain, which activates the substrate amino acid, form-
Chemistry & Biology [1], will facilitate the design and ing an amino acyl-AMP intermediate, prior to covalent
engineering of new, potentially life-saving antibiotics. attachment to the NRPS and peptide bond formation.
The same group has also shown that, by changing as
The calcium-dependent antibiotic daptomycin recently few as one amino acid residue at the active site of an
received approval for clinical use. Daptomycin is a tride- A domain, it is possible to change the specificity of
capeptide comprising several nonproteinogenic amino the A domain and generate a surfactin derivative with
acids with an N-terminal decanoyl fatty acid side chain altered sequence [12].
and a decapeptide lactone core resulting from the cycli- Biosynthetic engineering of nonribosomal peptides is
zation of the Thr-4 hydroxyl group onto the C-terminal achieved by reprogramming the genes that encode the
carboxylate (Figure 1). Daptomycin is produced as a key biosynthetic enzymes. It is therefore essential that
complex mixture of lipopeptides by Streptomyces ro- the biosynthetic gene cluster is first isolated, cloned,
seosporus [2] and shares a similar structure, and possi- and then sequenced. The recently completed S. coelico-
bly a related mode of action, to other acidic lipopeptide lor genome-sequencing project revealed the first entire
antibiotics. These include the calcium-dependent antibi- biosynthetic gene cluster of an acidic lipopeptide antibi-
otics (CDA) from Streptomyces coelicolor [3], A54145 otic, CDA. Using this genetic template, it was possible
from Streptomyces fradiae [4], and the friulimicins along to engineer the biosynthesis of new CDAs using a muta-
with amphomycins from Actinoplanes friuliensis [5]. No- synthesis approach [3]. To achieve this, a gene required
tably, all of these antibiotics possess N-terminal fatty for the biosynthesis of one of the unusual amino acids
acid moieties and decapeptide lactone or lactam rings in CDA, hydroxyphenylglycine (HPG), was deleted from
containing several acidic residues, which are important the gene cluster. Feeding synthetic analogs of HPG and
for calcium binding and antibacterial activity. Recently, its precursors resulted in CDAs with phenylglycine or
scientists at Ecopia Biosciences Inc. have used a geno- 4-fluorophenylglycine residues in place of HPG. Further
mics-based approach [6, 7] to identify numerous pre- attempts to engineer CDA have focused on active site
viously uncharacterized lipopeptide biosynthetic gene modification of A domains [13]. Changing two residues
clusters, suggesting that many more natural lipopeptide within one of the key Asp-activating A domains resulted
antibiotics have yet to be isolated. in CDA containing Asn instead of Asp at position 7.
The acidic lipopeptides belong to the nonribosomal Significantly, the new peptide is no longer bioactive,
peptide family of natural products. Nonribosomal pep- suggesting that Asp-7 is essential for calcium binding
tides are among the most structurally diverse and wide- and activity. Noticeably, yields of the new Asn-con-
spread secondary metabolites in nature and include taining CDA were reduced, and significant quantities of
important therapeutic agents, such as vancomycin, the CDA-hexapeptide intermediate were isolated, pre-
cyclosporin, and bleomycin, as well as daptomycin. sumably due to hydrolysis by an unidentified NRPS
Given their structural complexity, total synthesis is usu- proofreading activity. An elegant complementary chem-
ally unable to provide the quantity or diversity of prod- oenzymatic approach has also been used to generate
ucts required for drug development. As a result of this, CDA-like peptides. Here, the CDA NRPS thioesterase
there has been considerable effort aimed at understand- domain (or peptide cyclase) was used in vitro to cyclize
ing how these molecules are biosynthesized, with a view a number of synthetic CDA-like linear peptides with
to developing methods that will allow for the engineered C-terminal thioesters [14]. Cubist Pharmaceuticals, who
(or combinatorial) biosynthesis of novel variants [8, 9]. produce daptomycin under the trade name Cubicin,
Central to the biosynthesis of these peptides are the have also completed sequencing the daptomycin bio-
nonribosomal peptide synthetases (NRPS). These large synthetic gene cluster [15]. This will greatly facilitate
assembly-line enzymes contain multiple modules, each their biosynthetic engineering efforts toward second-
of which is responsible for the activation and incorpora- generation lipopeptide antibiotics (dapt-II).
tion of a specific amino acid into the growing peptide Daptomycin exhibits bactericidal activity against life-
chain. Using a combination of exquisite structural biol- threatening pathogens that are resistant to all current
ogy and enzymology, the function and substrate speci- treatments, including vancomycin, and represents the
ficities of the individual catalytic domains within NRPS first new class of natural antibiotic to reach the clinic in
modules have been elucidated [9]. Consequently, meth- many years. Not surprisingly, its arrival was met with
considerable interest and optimism [16]. Currently, dap-ods have been developed which have enabled the engi-
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Figure 1. The Structure of Daptomycin
tomycin is being used to treat skin infections, but trials antibiotics work [1, 17] and our capability to engineer
more potent variants [3, 8–14] should ensure that weare underway for its use to combat more dangerous
life-threatening infections including endocarditis. This is will win.
despite the fact that until now daptomycin’s 3D stucture
remained unknown, and its distinct mechanism of action Jason Micklefield
Department of Chemistrywas the subject of considerable debate. However, in
this issue of Chemistry & Biology, Hancock and cowork- University of Manchester Institute of Science
and Technologyers [1] describe the significant advances that they have
made toward answering these key questions. Using a PO Box 88
Manchester M60 1QDcombination of CD and fluorescence spectroscopy, they
show that daptomycin undergoes significant calcium- United Kingdom
dependent conformational changes upon association
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